Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A

Romi Gupta, Yuying Dong, Peter D. Solomon, Hiromi I. Wettersten, Christopher J. Cheng, JIn Na Min, Jeremy Henson, Shaillay Kumar Dogra, Sung H. Hwang, Bruce D. Hammock, Lihua J. Zhu, Roger R. Reddel, W. Mark Saltzman, Robert H Weiss, Sandy Chang, Michael R. Green, Narendra Wajapeyee

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Tumor suppressor p53 plays an important role in mediating growth inhibition upon telomere dysfunction. Here, we show that loss of the p53 target gene cyclin-dependent kinase inhibitor 1A (CDKN1A, also known as p21 WAF1/CIP1) increases apoptosis induction following telomerase inhibition in a variety of cancer cell lines and mouse xenografts. This effect is highly specific to p21, as loss of other checkpoint proteins and CDK inhibitors did not affect apoptosis. In telomerase, inhibited cell loss of p21 leads to E2F1- and p53-mediated transcriptional activation of p53-upregulated modulator of apoptosis, resulting in increased apoptosis. Combined genetic or pharmacological inhibition of telomerase and p21 synergistically suppresses tumor growth. Furthermore, we demonstrate that simultaneous inhibition of telomerase and p21 also suppresses growth of tumors containing mutant p53 following pharmacological restoration of p53 activity. Collectively, our results establish that inactivation of p21 leads to increased apoptosis upon telomerase inhibition and thus identify a genetic vulnerability that can be exploited to treat many human cancers containing either wild-type or mutant p53.

Original languageEnglish (US)
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number30
DOIs
StatePublished - 2014

Fingerprint

Telomerase
Apoptosis
Neoplasms
Growth
Pharmacology
Cyclin-Dependent Kinases
p53 Genes
Telomere
Heterografts
Transcriptional Activation
Cell Line
Proteins

ASJC Scopus subject areas

  • General

Cite this

Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. / Gupta, Romi; Dong, Yuying; Solomon, Peter D.; Wettersten, Hiromi I.; Cheng, Christopher J.; Min, JIn Na; Henson, Jeremy; Dogra, Shaillay Kumar; Hwang, Sung H.; Hammock, Bruce D.; Zhu, Lihua J.; Reddel, Roger R.; Saltzman, W. Mark; Weiss, Robert H; Chang, Sandy; Green, Michael R.; Wajapeyee, Narendra.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 30, 2014.

Research output: Contribution to journalArticle

Gupta, R, Dong, Y, Solomon, PD, Wettersten, HI, Cheng, CJ, Min, JIN, Henson, J, Dogra, SK, Hwang, SH, Hammock, BD, Zhu, LJ, Reddel, RR, Saltzman, WM, Weiss, RH, Chang, S, Green, MR & Wajapeyee, N 2014, 'Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 30. https://doi.org/10.1073/pnas.1411370111
Gupta, Romi ; Dong, Yuying ; Solomon, Peter D. ; Wettersten, Hiromi I. ; Cheng, Christopher J. ; Min, JIn Na ; Henson, Jeremy ; Dogra, Shaillay Kumar ; Hwang, Sung H. ; Hammock, Bruce D. ; Zhu, Lihua J. ; Reddel, Roger R. ; Saltzman, W. Mark ; Weiss, Robert H ; Chang, Sandy ; Green, Michael R. ; Wajapeyee, Narendra. / Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 30.
@article{9d058bb6d43548378b587f380cebee31,
title = "Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A",
abstract = "Tumor suppressor p53 plays an important role in mediating growth inhibition upon telomere dysfunction. Here, we show that loss of the p53 target gene cyclin-dependent kinase inhibitor 1A (CDKN1A, also known as p21 WAF1/CIP1) increases apoptosis induction following telomerase inhibition in a variety of cancer cell lines and mouse xenografts. This effect is highly specific to p21, as loss of other checkpoint proteins and CDK inhibitors did not affect apoptosis. In telomerase, inhibited cell loss of p21 leads to E2F1- and p53-mediated transcriptional activation of p53-upregulated modulator of apoptosis, resulting in increased apoptosis. Combined genetic or pharmacological inhibition of telomerase and p21 synergistically suppresses tumor growth. Furthermore, we demonstrate that simultaneous inhibition of telomerase and p21 also suppresses growth of tumors containing mutant p53 following pharmacological restoration of p53 activity. Collectively, our results establish that inactivation of p21 leads to increased apoptosis upon telomerase inhibition and thus identify a genetic vulnerability that can be exploited to treat many human cancers containing either wild-type or mutant p53.",
author = "Romi Gupta and Yuying Dong and Solomon, {Peter D.} and Wettersten, {Hiromi I.} and Cheng, {Christopher J.} and Min, {JIn Na} and Jeremy Henson and Dogra, {Shaillay Kumar} and Hwang, {Sung H.} and Hammock, {Bruce D.} and Zhu, {Lihua J.} and Reddel, {Roger R.} and Saltzman, {W. Mark} and Weiss, {Robert H} and Sandy Chang and Green, {Michael R.} and Narendra Wajapeyee",
year = "2014",
doi = "10.1073/pnas.1411370111",
language = "English (US)",
volume = "111",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "30",

}

TY - JOUR

T1 - Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A

AU - Gupta, Romi

AU - Dong, Yuying

AU - Solomon, Peter D.

AU - Wettersten, Hiromi I.

AU - Cheng, Christopher J.

AU - Min, JIn Na

AU - Henson, Jeremy

AU - Dogra, Shaillay Kumar

AU - Hwang, Sung H.

AU - Hammock, Bruce D.

AU - Zhu, Lihua J.

AU - Reddel, Roger R.

AU - Saltzman, W. Mark

AU - Weiss, Robert H

AU - Chang, Sandy

AU - Green, Michael R.

AU - Wajapeyee, Narendra

PY - 2014

Y1 - 2014

N2 - Tumor suppressor p53 plays an important role in mediating growth inhibition upon telomere dysfunction. Here, we show that loss of the p53 target gene cyclin-dependent kinase inhibitor 1A (CDKN1A, also known as p21 WAF1/CIP1) increases apoptosis induction following telomerase inhibition in a variety of cancer cell lines and mouse xenografts. This effect is highly specific to p21, as loss of other checkpoint proteins and CDK inhibitors did not affect apoptosis. In telomerase, inhibited cell loss of p21 leads to E2F1- and p53-mediated transcriptional activation of p53-upregulated modulator of apoptosis, resulting in increased apoptosis. Combined genetic or pharmacological inhibition of telomerase and p21 synergistically suppresses tumor growth. Furthermore, we demonstrate that simultaneous inhibition of telomerase and p21 also suppresses growth of tumors containing mutant p53 following pharmacological restoration of p53 activity. Collectively, our results establish that inactivation of p21 leads to increased apoptosis upon telomerase inhibition and thus identify a genetic vulnerability that can be exploited to treat many human cancers containing either wild-type or mutant p53.

AB - Tumor suppressor p53 plays an important role in mediating growth inhibition upon telomere dysfunction. Here, we show that loss of the p53 target gene cyclin-dependent kinase inhibitor 1A (CDKN1A, also known as p21 WAF1/CIP1) increases apoptosis induction following telomerase inhibition in a variety of cancer cell lines and mouse xenografts. This effect is highly specific to p21, as loss of other checkpoint proteins and CDK inhibitors did not affect apoptosis. In telomerase, inhibited cell loss of p21 leads to E2F1- and p53-mediated transcriptional activation of p53-upregulated modulator of apoptosis, resulting in increased apoptosis. Combined genetic or pharmacological inhibition of telomerase and p21 synergistically suppresses tumor growth. Furthermore, we demonstrate that simultaneous inhibition of telomerase and p21 also suppresses growth of tumors containing mutant p53 following pharmacological restoration of p53 activity. Collectively, our results establish that inactivation of p21 leads to increased apoptosis upon telomerase inhibition and thus identify a genetic vulnerability that can be exploited to treat many human cancers containing either wild-type or mutant p53.

UR - http://www.scopus.com/inward/record.url?scp=84905025474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905025474&partnerID=8YFLogxK

U2 - 10.1073/pnas.1411370111

DO - 10.1073/pnas.1411370111

M3 - Article

C2 - 25024194

AN - SCOPUS:84905025474

VL - 111

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 30

ER -